Dr Richard McFarlane
- Clinical Research Fellow (Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Hotjar and Clarity help us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Sykes, R. and McFarlane, R. (2023) Icosapent ethyl and plaque regression: insights from the EVAPORATE-FFRCT study. European Heart Journal: Cardiovascular Imaging, 24(7), pp. 874-875. (doi: 10.1093/ehjci/jead086) (PMID:37119308)
Morrow, A. J. , McFarlane, R. and Berry, C. (2023) Novel therapy for ischaemia with no obstructive coronary arteries. European Heart Journal, (doi: 10.1093/eurheartj/ehad391) (PMID:37377290) (Early Online Publication)
Sykes, R. A. et al. (2023) Vascular mechanisms of post-COVID-19 conditions: rho-kinase is a novel target for therapy. European Heart Journal: Cardiovascular Pharmacotherapy, 9(4), pp. 371-386. (doi: 10.1093/ehjcvp/pvad025) (PMID:37019821) (PMCID:PMC10236521)
Sykes, R. and McFarlane, R. (2023) Icosapent ethyl and plaque regression: insights from the EVAPORATE-FFRCT study. European Heart Journal: Cardiovascular Imaging, 24(7), pp. 874-875. (doi: 10.1093/ehjci/jead086) (PMID:37119308)
Morrow, A. J. , McFarlane, R. and Berry, C. (2023) Novel therapy for ischaemia with no obstructive coronary arteries. European Heart Journal, (doi: 10.1093/eurheartj/ehad391) (PMID:37377290) (Early Online Publication)
Sykes, R. A. et al. (2023) Vascular mechanisms of post-COVID-19 conditions: rho-kinase is a novel target for therapy. European Heart Journal: Cardiovascular Pharmacotherapy, 9(4), pp. 371-386. (doi: 10.1093/ehjcvp/pvad025) (PMID:37019821) (PMCID:PMC10236521)